Login / Signup

Anti-IL17A, Ixekizumab, for treatment-resistant chronic venous leg ulcers: a phase II randomized, double-blind, placebo-controlled pilot trial.

Charlotte CoxK FryY SivakumaranL SpelmanKiarash Khosrotehrani
Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Keyphrases
  • phase ii
  • placebo controlled
  • double blind
  • phase iii
  • clinical trial
  • phase ii study
  • study protocol
  • randomized controlled trial
  • squamous cell carcinoma
  • radiation therapy
  • rectal cancer